Core Viewpoint - Southwest Securities predicts that the revenue of Insilico Medicine (03696) will reach $0.59 billion, $1.55 billion, and $2.02 billion for the years 2025-2027, with corresponding price-to-sales (PS) ratios of 78x, 30x, and 23x. The company's AI platform innovation capability has been validated, and long-term development is promising as more pipeline assets enter clinical stages and external licensing opportunities arise. The report initiates coverage with a recommendation for active attention [1]. Group 1: Core Competitiveness - The company's core competitiveness lies in its self-developed, globally leading end-to-end generative AI platform, Pharma.AI, which reduces the time from target discovery to clinical candidate confirmation from the industry average of 4.5 years to 12-18 months, validated through over 40 projects and 27 PCCs [2]. - The primary business model focuses on drug discovery and pipeline development, including external licensing, collaborative development, and independent development. Since 2026, the company has achieved three business development (BD) collaborations with upfront payments totaling $0.42 billion, and a total potential value of $10.74 billion. More BD collaborations are expected in 2026, potentially catalyzing stock price growth [1][3]. Group 2: Business Model - The company employs a dual-engine business model: 1) drug discovery and pipeline development through external licensing or collaborative development to obtain upfront payments, milestone payments, and sales shares; 2) software solutions generating subscription revenue from licensing the Pharma.AI platform. This model has been validated in the market, with nine external licensing agreements totaling over $4 billion in potential value and partnerships with 13 of the top 20 global pharmaceutical companies [3]. - The technology licensing generates cash flow and extensive validation data, while the success of internal pipelines further validates and enhances the AI platform's capabilities, creating a strong "data flywheel" effect [3]. Group 3: Pipeline and Product Potential - The company has nearly 20 clinical or IND application-stage assets generated from its platform, with the fastest pipeline, ISM001-055, being the world's first fully AI-discovered and designed candidate drug that has completed Phase IIa clinical trials for treating idiopathic pulmonary fibrosis (IPF). Recent clinical results show that patients receiving treatment exhibited dose-dependent improvements in lung function, with a significant difference of 118.7 milliliters compared to the placebo group [4]. - The IPF market presents substantial opportunities, and if ISM001-055 successfully reaches the market, it could become a disruptive therapy [4].

智通财经APP获悉，西南证券发布研报称，预计英矽智能(03696)2025-2027年对应营业收入分别为 0.59、1.55和2.02亿美元，对应PS为78倍、30倍和23倍。公司AI平台创新能力得到验证，长期发展值得 期待，随着更多管线资产进入临床和对外授权，公司有望迎来持续的价值兑现。首次覆盖，建议积极关 注。 西南证券主要观点如下： 公司核心竞争力在于其自研的全球领先的端到端生成式AI平台Pharma.AI 1）该平台将从靶点发现到临床前候选化合物确认的时间从行业平均的4.5年缩短至12-18个月，已通过 40+的项目，27个PCC得到充分验证；2）公司主要业务模式为药物发现及管线开发，包括对外授权、合 作开发和自主开发，26年至今公司已达成3项BD合作，首付款达0.42亿美元（含近期研发里程碑），总 金额达10.74亿美元。随着公司商业价值得到验证，26年有望达成更多BD合作，带来股价的直接催化； 3）自主开发的核心管线ISM001-055为全球AI制药唯一一款取得Ⅱ期临床数据的全AI研发药物，未来有 望成为颠覆性疗法，迎来持续的价值兑现。 全球领先的端到端AI制药平台，构筑核心技术壁垒 公司核心竞争 ...

Group 1 - The core viewpoint is that various institutions maintain "buy" ratings for different companies, highlighting their growth potential and strategic partnerships [1][2][3][4][5][6][7][8][9][10] Group 2 - China-based pharmaceutical company, Stone Pharmaceutical Group, has entered a significant $18.5 billion strategic collaboration with AstraZeneca, focusing on long-acting GLP-1/GIPR dual-target peptides and multiple obesity/diabetes pipelines, enhancing its AI-driven drug discovery capabilities [1][2] - Baidu Group's cloud business has shown a 10% year-on-year growth in Q4, driven by intelligent cloud infrastructure, with AI-native marketing services now covering 70% of search result pages [3] - Sunny Optical Technology is projected to see a 70-75% increase in net profit by 2025, benefiting from improved ASP and gross margin in mobile lenses and modules [4] - InSilico Medicine has secured over HKD 930 million in cardiovascular metabolic collaborations, continuing its partnerships with major pharmaceutical companies, and has produced 27 preclinical candidate molecules through its Pharma.AI platform [5][6] - Kuaishou Technology is enhancing its platform with advanced AI models, which are expected to improve user engagement and profitability [6] - Decon Agriculture is expected to achieve a target price of HKD 87, with a stable cost structure and leading efficiency in pig farming [7] - Dongfang Zhenxuan has exceeded profit expectations by 68% in the first half of FY26, with self-operated product GMV rising to 52.8% [8] - Hang Lung Properties is experiencing a recovery in retail sales, with Q3/Q4 growth rates of 10% and 18%, respectively, and an improved tenant mix [10]

Group 1 - The core viewpoint of the article highlights that the AI-driven drug discovery and development company, Insilico Medicine (3696.HK), experienced a significant stock increase of 14%, reaching a price of 68.7 HKD, with its market capitalization approaching 40 billion HKD [1] Group 2 - The article emphasizes the growing interest and investment in AI technologies within the pharmaceutical industry, particularly in drug discovery and development processes [1] - Insilico Medicine's performance reflects broader trends in the market, showcasing the potential for AI to transform traditional pharmaceutical practices [1] - The increase in stock price indicates positive investor sentiment and confidence in the company's future prospects and innovations in AI applications [1]

Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Insilico Medicine (3696.HK) by 14%, reaching HKD 68.7, with a market capitalization approaching HKD 40 billion [1] - Insilico Medicine announced the completion of the first patient dosing in Phase I clinical trials for the MEN2501 project, which is licensed to Menarini Group [1] - As part of the collaboration agreement, Insilico Medicine received a milestone payment of approximately HKD 39 million from Menarini [1] Group 2 - MEN2501, previously known as ISM9682, is a highly differentiated small molecule inhibitor targeting the KIF18A protein, showing significant inhibitory activity against chromosomal instability cancers in preclinical data [1]

Core Viewpoint - The AI-driven drug discovery and development company Insilico Medicine (3696.HK) experienced a significant stock increase of 14%, reaching HKD 68.7, with a market capitalization approaching HKD 40 billion following the announcement of a milestone payment from Menarini Group for the MEN2501 project [1] Company Summary - Insilico Medicine has authorized the MEN2501 project to Menarini Group, which has successfully completed the first patient dosing in Phase I clinical trials [1] - The company received a milestone payment of approximately HKD 39 million from Menarini as part of their collaboration agreement [1] - MEN2501, previously known as ISM9682, is a highly differentiated small molecule inhibitor targeting the driver protein KIF18A, showing significant inhibitory activity against chromosomal instability cancers in preclinical data [1]

机构：国海证券 研究员：曹泽运/万鹏辉 投资要点: 持续达成研发合作，AI 制药能力不断被认可2021 年至今，公司已于多家国内外龙头药企达成研发合 作，其中2022 年跟赛诺菲达成最高12 亿美元+特许权使用费合作，2025 年跟礼来达成超1 亿美元+特许 权使用费合作，2026 年与施维雅达成多年期抗肿瘤药物研发合作，协议总金额高达8.88 亿美元。多家 国内外龙头药企陆续跟公司达成AI 平台研发合作，公司AI 平台研发能力不断被认可。 已有多款自研管线对外授权2023 年至今，公司已经完成3 笔对外自主研发管线的对外授权，分别为： 2023 年对EXELIXIS 授权USP1 靶点药物，总金额接近10 亿美元，其中首付款8000 万美元；2023 年对 Menarini 授权KAT6 小分子，总金额超过5 亿美元，其中首付款1200 万美元；2024 年继续对Menarini 授 权，总金额超过5.5亿美元，首付款2000 万美元，2025 年12 月授权太景PHD 抑制剂ISM4808 大中华区 开发、商业化和再许可权力，交易总额达数千万美元，以上均包含特许权使用费。2026 年1 月，对衡泰 生物授 ...

Core Viewpoint - Incyte Corporation (03696) experienced a significant stock increase of over 4%, reaching HKD 63, following the announcement of a milestone payment from Menarini Group related to the MEN2501 project [1] Group 1: Financial Performance - As of the report, Incyte's stock rose by 4.56%, with a trading volume of HKD 1.323 million [1] - The company received approximately HKD 39 million as a milestone payment from Menarini for the MEN2501 project [1] Group 2: Project Development - MEN2501, previously known as ISM9682, is a small molecule inhibitor targeting the KIF18A protein, showing significant inhibitory activity against chromosomal instability cancers in preclinical data [1] - The collaboration with Menarini Group, valued at USD 550 million (approximately HKD 4.29 billion), aims to accelerate the development of transformative anti-tumor therapies [1]

消息面上，2月3日，英矽智能发布公告，英矽智能对外授权给美纳里尼集团(美纳里尼)的MEN2501项目 已在I期临床试验中完成首例患者给药，根据双方合作协议，英矽智能获得由美纳里尼支付的约3900万 港元的最新里程碑付款。 智通财经APP获悉，英矽智能(03696)高开逾4%，截至发稿，涨4.56%，报63港元，成交额132.3万港 元。 MEN2501(曾被称为ISM9682)是一款具备高度差异化的小分子抑制剂，靶向驱动蛋白KIF18A，临床前数 据显示对染色体不稳定性癌症具有显著的抑制活性。此前，作为一项旨在加速变革性抗肿瘤疗法开发的 战略合作，英矽智能以5.5亿美元(等值于约42.9亿港元)合作总额将MEN2501项目对外授权给美纳里尼集 团全资子公司Stemline Therapeutics Inc.。 ...

格隆汇2月3日丨英矽智能(03696.HK)宣布，英矽智能对外授权给美纳里尼集团("美纳里尼")的MEN2501 项目已在I期临床试验中完成首例患者给药，根据双方合作协议，英矽智能获得由美纳里尼支付的约 3,900万港元的最新里程碑付款。 MEN2501(曾被称为ISM9682)是一款具备高度差异化的小分子抑制剂，靶向驱动蛋白KIF18A，临床前数 据显示对染色体不稳定性癌症具有显着的抑制活性。此前，作为一项旨在加速变革性抗肿瘤疗法开发的 战略合作，英矽智能以5.5亿美元(等值于约42.9亿港元)合作总额将MEN2501项目对外授权给美纳里尼集 团全资子公司Stemline Therapeutics Inc.。 来源：格隆汇APP ...